Renishaw Neuromate Frameless Gen II Cleared by the FDA
Stereotactic robot has application in broad range of neurosurgical procedures, first U.S. installation at Philadelphia’s Thomas Jefferson University Hospital.
The U.S. Food and Drug administration (FDA) has issued clearance for Renishaw’s neuromate® frameless Gen II stereotactic robotic system. Neuromate provides a platform for a broad range of functional neurosurgical procedures including electrode implantation for deep brain stimulation, and applications in neuroendoscopy, biopsy and other research applications. The robot - a Class II medical device (USA)/Class IIb (EU) – provides consistent, rapid and precise targeting in stereotactic procedures, and can be used with a stereotactic frame, or in frameless mode for reduced patient trauma. It is compatible with procedures that use either general or local anesthesia.
“We are excited to launch our newest generation neuromate robotic system in the US, which is the largest global market for medical devices, said Dr. Abed Hammoud, CEO of Renishaw Mayfield SA. “Our clinical solutions and technical support teams are looking forward to working with some of the leading centers in the U.S. and establishing robotics in the neuro operating room.”
The first neuromate system in the U.S. is installed at the neurosurgery department of the Thomas Jefferson University Hospital in Philadelphia. Ashwini D. Sharan, MD, Professor and Director of the Sidney Kimmel Medical College Department of Neurological Surgery, and his colleague Dr. Chengyuan Wu, Consulting Neurosurgeon, performed the first case using the robotic system for a Stereo-EEG implantation case in epilepsy.
"We believe this is only the beginning of an exciting future for robotics in the neurosurgery operating room," said Dr. Sharan.
A Renishaw neuromate system is also installed at The Ohio State University Wexner Medical Center, where it was used to perform the first Deep Brain Stimulation (DBS) in the US. Ali Rezai, MD, Professor of Neurosurgery and Neuroscience and Director, OSU Center for Neuromodulation, is the head of the team that used the neuromata system to implant DBS electrodes. Based on the first procedure, he says, “We believe that robotic technology has an exciting future in the neurosurgery operating rooms for DBS, brain infusion, endoscopy and other applications. We saw both procedural and time saving advantages.”
For more information on neuromata, visit www.renishaw.com/neuromate.
About Renishaw
Renishaw is a global company with core skills in measurement, motion control, spectroscopy, neurosurgical products and precision machining. The company has 3,800 employees based at offices in 32 countries, and is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250. For more information visit www.renishaw.com.
Contact:
Jeff Seliga
Renishaw Inc.
Tel: 847.286.9953
jeffrey.seliga@renishaw.com
Jeff Drum
Kemble Drum Communications, Inc.
Tel: 513.871.4042
jdrum@kembledrum.com
Inquiries:
In USA:
Susan Wilm
Marketing Assistant
Renishaw Inc.
5277 Trillium Blvd.
Hoffman Estates, IL 60192
susan.wilm@renishaw.com Â
Tel: 847.286.9953
In Canada:
Dafydd Williams
General Manager
Renishaw (Canada) Limited
2180 Dunwin Drive, Unit #1
Mississauga ONT L5L 5M8
dafydd.williams@renishaw.com
Tel: 905.828.0104
